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Further analyses of the safety of
verubecestat in the phase 3 EPOCH trial of
mild-to-moderate Alzheimer’s disease
Michael F. Egan1,6*, Yuki Mukai1, Tiffini Voss1, James Kost1, Julie Stone1, Christine Furtek1, Erin Mahoney1,
Jeffrey L. Cummings2, Pierre N. Tariot3, Paul S. Aisen4, Bruno Vellas5, Christopher Lines1 and David Michelson1
Abstract
Background: Verubecestat, a BACE1 inhibitor that reduces Aβ levels in the cerebrospinal fluid of humans, was not
effective in a phase 3 trial (EPOCH) of mild-to-moderate AD and was associated with adverse events. To assist in the
development of BACE1 inhibitors, we report detailed safety findings from EPOCH.
Methods: EPOCH was a randomized, double-blind, placebo-controlled 78-week trial evaluating verubecestat 12 mg
and 40 mg in participants with mild-to-moderate AD diagnosed clinically. The trial was terminated due to futility
close to its scheduled completion. Of 1957 participants who were randomized and took treatment, 652 were
assigned to verubecestat 12 mg, 652 to verubecestat 40 mg, and 653 to placebo. Adverse events and relevant
laboratory, vital sign, and ECG findings were assessed.
Results: Verubecestat 12 mg and 40 mg were associated with an increase in the percentage of participants
reporting adverse events versus placebo (89 and 92% vs. 82%), although relatively few participants discontinued
treatment due to adverse events (8 and 9% vs. 6%). Adverse events that were increased versus placebo included
falls and injuries, suicidal ideation, weight loss, sleep disturbance, rash, and hair color change. Most were mild to
moderate in severity. Treatment differences in suicidal ideation emerged within the first 3 months but did not
appear to increase after 6 months. In contrast, treatment differences in falls and injuries continued to increase over
time.
Conclusions: Verubecestat was associated with increased risk for several types of adverse events. Falls and injuries
were notable for progressive increases over time. While the mechanisms underlying the increased adverse events
are unclear, they may be due to BACE inhibition and should be considered in future clinical development programs
of BACE1 inhibitors.
Trial registration: ClinicalTrials.gov NCT01739348, registered on 29 November 2012.
Keywords: Verubecestat, BACE inhibitor, Amyloid, Alzheimer’s disease, Clinical trial, Safety
Background
The amyloid hypothesis of Alzheimer’s disease (AD) pro-
poses that amyloid-β (Aβ) peptide aggregates trigger the
spreading of tau-related neurofibrillary tangles and sub-
sequent, downstream, neuronal degeneration [1–3]. Aβ
is the result of sequential cleavage of amyloid precursor
protein (APP) by β-site APP cleaving enzyme 1 (BACE1;
also known as β-secretase) and γ-secretase. Inhibition of
BACE1 is a potential therapeutic strategy for disease
modification in AD by decreasing amyloid production
[4]. Previous approaches targeting reduction of amyloid
have been associated with adverse effects including
amyloid-related imaging abnormalities (ARIAs) with
edema or hemorrhage in the case of monoclonal anti-
bodies and worsening of cognition and function along
with suspected notch-related symptoms in the case of γ-
secretase inhibitors [5–9]. Safety concerns about BACE1
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inhibition have arisen on the basis of BACE1’s diverse
physiological functions and wide range of substrates, as
well as the results of studies of BACE1 inhibition in ani-
mals [10, 11]. These studies have suggested that BACE
inhibition could, among other effects, potentially impair
cognition, myelination, and muscle spindle formation
and maintenance, and result in psychosis, skin
hypopigmentation, and retinal degeneration.
Verubecestat was the first BACE1 inhibitor to pro-
gress to late-stage clinical trials in AD patients. Its
chemical, preclinical, and clinical pharmacological
profile has been previously described [12, 13]. It is an
inhibitor of BACE2 in addition to BACE1. In a phase
3 clinical trial (EPOCH), verubecestat doses of 12 mg
and 40 mg were ineffective at slowing the rate of cog-
nitive or functional decline over 78 weeks in partici-
pants with mild-to-moderate AD, despite reducing
cerebrospinal fluid levels of Aβ by 63 to 81% [14]. Al-
though the outcome of EPOCH was disappointing,
BACE1 inhibition requires more study; administration
earlier in the AD process, altering dosing strategies,
and use in combination therapies are all possible fu-
ture application of BACE1 inhibitors. Future use of
BACE1 inhibitors requires a clear understanding of
the benefit/risk profile associated with an experimen-
tal treatment.
We previously reported that in EPOCH, chronic
treatment for 78 weeks with verubecestat 12 mg and
40 mg was associated with an increase in the percent-
age of participants reporting adverse events versus
placebo (89 and 92% vs. 82%), although relatively few
participants discontinued treatment due to adverse
events (8 and 9% vs. 6%) [14]. Specific adverse events
for verubecestat versus placebo included falls and in-
juries (20 and 23% vs. 16%), rash (12 and 10% vs.
6%), sleep disturbance (10 and 8% vs. 5%), suicidal
ideation (6 and 6% vs. 3%), weight loss (6 and 6% vs.
3%), and hair color change (2 and 3% vs. 0%).
Other EPOCH findings of potential relevance to
the safety of BACE1 inhibitors include the observa-
tion that there was a modest initial worsening in
mean cognition scores for verubecestat versus pla-
cebo at week 13 that was not maintained at week 78
[14] and the observation in a magnetic resonance
imaging (MRI) substudy of a greater decline in hip-
pocampal volume for verubecestat versus placebo
that was apparent from week 13 but did not increase
thereafter [15].
Given that EPOCH constitutes the most comprehen-
sive safety database currently available for a BACE1 in-
hibitor (nearly 2000 randomized participants), we report
here on detailed analyses of the safety profile of verube-
cestat in the mild-to-moderate AD population to help
inform further development of BACE1 inhibitors.
Methods
Full details of the trial methods have been previously re-
ported [14]. The trial protocol is included as Add-
itional file 1. Relevant details for the present paper are
summarized below.
Participants
Eligible participants were aged 55–85 years inclusive and
met the standard research and clinical criteria for prob-
able AD dementia [16, 17]. All participants had brain
MRI, or computerized tomography if MRI was contrain-
dicated, to exclude alternative causes of dementia and a
score of 15–26 on the Mini-Mental State Examination
(MMSE) [18]. Participants could be taking an acetyl-
cholinesterase inhibitor and/or memantine provided
they were on stable doses prior to screening. Other than
the diagnosis of AD, participants were required to be in
good general health with no evidence of a current clinic-
ally significant neurological, psychiatric, or general med-
ical condition.
Design and treatment
The trial was conducted at 238 centers in 21 countries
from November 2012 to April 2017. The trial consisted
of a randomized, double-blind, placebo-controlled, par-
allel group, 78-week treatment period (part I) followed
by an optional extension period with a planned duration
of up to 5 years (part II). In part I, participants were ran-
domized to verubecestat 12 mg, 40 mg, or placebo. Par-
ticipants who completed the part I 78-week treatment
period could enter the part II extension in which pla-
cebo participants were switched to 40 mg while those on
12mg or 40 mg remained on the same dose (all in a
blinded fashion).
A decision to stop the trial was made in February 2017
at the independent external Data Monitoring Commit-
tee’s recommendation, based on futility. At the time of
the decision, all participants had been enrolled and part
I was 5 months from its scheduled completion. None of
the participants who entered part II (the extension)
completed this phase of the trial due to the trial
termination.
Safety assessments
Safety was assessed by adverse event reports and by rou-
tine laboratory analyses, electrocardiograms (ECGs), and
physical examinations. Routine MRI was initially per-
formed to assess possible ARIAs but was discontinued
partway through the trial based on external Data Moni-
toring Committee and regulatory feedback that it was no
longer required. Comprehensive dermatological and
ophthalmological exams were also performed at baseline
and selected follow-up clinic visits. The ophthalmo-
logical findings will be the subject of a separate report,
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but there were no significant treatment effects. Derma-
tology exams were performed by a dermatologist at
baseline and week 26 of treatment and by the site phys-
ician using a directed skin examination at weeks 13, 52,
and 78 of treatment. Suicidality was assessed by the
Columbia Suicide Severity Rating Scale (C-SSRS) [19] at
every clinic visit. The Neuropsychiatric Inventory (NPI)
[20] was administered at baseline and weeks 8, 13, 26,
52, and 78. Certain adverse events were prespecified as
events of clinical interest (ECI), based on the signals ob-
served in preclinical or phase 1 studies with verubecestat
or signals observed for other amyloid-lowering treat-
ments, and were subject to additional reporting require-
ments as detailed in the trial protocol. These included
ARIAs, suicidal ideation, rash, and hypopigmentation.
Statistical analysis
The present analyses focused on data from the part I
placebo-controlled 78-week treatment phase. All treated
participants were used in safety analyses. Adverse events
within 14 days postdose were collected verbatim and
mapped to Medical Dictionary for Regulatory Activities
(MedDRA) version 20.0 lower-level terms which were
then mapped to preferred terms and system organ clas-
ses. In addition, selected adverse event terms were clus-
tered in an unblinded and post hoc manner to form
“composite” adverse event groupings of related adverse
events. The composite adverse events included rash/
dermatitis/urticaria, delirium-like events, psychotic
symptoms (hallucinations and delusions), injuries and
falls, overactive bladder events, sleep disturbance events,
and syncopal-like events. Exposure-response relation-
ships were calculated for select preferred or composite
adverse event terms. The numbers of participants ex-
ceeding predefined limits of change for laboratory, ECG,
and vital sign measures were calculated. Additional ana-
lyses were performed as detailed in the relevant sections.
All statistical analyses were performed using SAS Ver-
sions 9.3 and 9.4 (SAS Institute, Cary, NC, USA).
Exposure-response analysis
A previously established population pharmacokinetic
model was used to estimate the verubecestat exposure
(area under the curve over the dosing interval at steady-
state, AUC0–24 h) for each participant (n = 1465) receiv-
ing treatment with verubecestat based on concentrations
collected during 4–7 visits. Time-weighted exposure was
determined based on the average exposure over the total
number of days on active treatment. The PROC LOGIS-
TIC procedure in SAS was used to develop logistic re-
gression models to relate drug exposure to dichotomous
endpoints (absence or presence of an adverse event).
Conclusions with respect to whether an exposure-
response relationship existed for a given endpoint was
based on testing for significance (P < 0.05) that the slope
of the linear AUC0–24 h relationship was different from
zero based on a fit of the active treated participants only.
Results
Participants
Participant disposition and demographics have been de-
scribed previously [14]. Of the 1957 randomized partici-
pants who were treated with verubecestat 12 mg, 40 mg,
or placebo, 1389 (70–72% in each group) completed part
I. The main reasons for discontinuation were trial ter-
mination and adverse events. At baseline, the mean age
of participants was 72 years (range 55 to 86), 55% were
women, 52% were classified as AD of moderate severity
based on MMSE score of ≤ 20 (48% had dementia of
mild severity based on MMSE score of ≥ 21), and 89%
were taking an acetylcholinesterase inhibitor and/or
memantine.
Safety overview
Adverse events by system organ class and preferred term
are summarized in Table 1. System organ classes with a
preferred term that showed an increase in at least one
verubecestat group versus placebo (defined as the lower
bound of the 95% confidence interval [CI] for the differ-
ence vs. placebo being > 0) were gastrointestinal (diar-
rhea, gastritis), infections/infestations (conjunctivitis),
injury (head injury, skin abrasion), investigations (weight
decreased), musculoskeletal (muscle spasms, pain in ex-
tremity), nervous system (dizziness), psychiatric (anxiety,
insomnia, sleep disorder, suicidal ideation), renal/urinary
(hypertonic bladder), and skin/subcutaneous (alopecia,
hair color changes, urticaria). Composite adverse events
that showed an increase in at least one verubecestat
group versus placebo (defined as above) were injury or
fall, overactive bladder symptoms, psychotic symptoms,
rash/dermatitis/urticaria, and sleep disturbance (Table 2).
Although numerically the results in Tables 1 and 2 sug-
gested a dose-response trend (more adverse events in
the 40 mg group compared to 12mg), the results of
exposure-response modeling suggested no significant
exposure-response effects for the adverse events evalu-
ated (Table 3).
With regard to the percentage of participants exceed-
ing predefined limits of change in the vital signs, more
participants on verubecestat 12 mg and 40 mg showed a
≥ 7% decrease in weight versus placebo (23.7 and 29.4%
vs. 13.1%) and fewer participants on verubecestat 12 mg
and 40 mg showed a ≥ 7% increase in weight versus pla-
cebo (7.1 and 8.0% vs. 15.5%) (Additional file 2: Table
S1). No treatment differences were seen in the percent-
ages of participants exceeding predefined limits of
change for other vital signs (Additional file 2: Table S1),
ECG measures (Additional file 2: Table S1), liver
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Table 1 Summary of adverse events by system organ class
System organ class Number (%) Treatment difference (95% CIa)
12 mg (N = 652) 40 mg (N = 652) Placebo (N = 653) 12 mg vs. placebo 40 mg vs. placebo
Any
≥ 1 adverse event 582 (89.3) 601 (92.2) 533 (81.6) 7.64 (3.84, 11.48) 10.55 (6.96, 14.23)
Gastrointestinal
Diarrhea 53 (8.1) 57 (8.7) 38 (5.8) 2.31 (− 0.46, 5.14) 2.92 (0.10, 5.81)
Gastritis 11 (1.7) 9 (1.4) 3 (0.5) 1.23 (0.13, 2.59) 0.92 (− 0.14, 2.20)
Infections
Conjunctivitis 5 (0.8) 13 (2.0) 4 (0.6) 0.15 1.38 (0.17, 2.84)
Injury
Head injury 3 (0.5) 9 (1.4) 2 (0.3) 0.15 1.07 (0.10, 2.33)
Skin abrasion 9 (1.4) 15 (2.3) 6 (0.9) 0.46 (− 0.78, 1.79) 1.38 (0.02, 2.95)
Investigations
Weight decreased 42 (6.4) 42 (6.4) 20 (3.1) 3.38 (1.10, 5.81) 3.38 (1.10, 5.81)
Metabolism/nutrition
Decreased appetite 16 (2.5) 29 (4.4) 16 (2.5) 0.00 (− 1.76, 1.77) 2.00 (0.02, 4.11)
Musculoskeletal and connective tissue
Muscle spasms 9 (1.4) 16 (2.5) 6 (0.9) 0.46 (− 0.78, 1.79) 1.54 (0.15, 3.13)
Pain in extremity 14 (2.1) 20 (3.1) 8 (1.2 0.92 (− 0.52, 2.49) 1.84 (0.29, 3.60)
Nervous system
Dizziness 31 (4.8) 53 (8.1) 32 (4.9) − 0.15 (− 2.53, 2.23) 3.23 (0.56, 5.99)
Psychiatric
Anxiety 39 (6.0) 46 (7.1) 24 (3.7) 2.31 (− 0.02, 4.73) 3.38 (0.96, 5.93)
Insomnia 35 (5.4) 29 (4.4) 20 (3.1) 2.31 (0.13, 4.60) 1.39 (− 0.70, 3.55)
Sleep disorder 18 (2.8) 8 (1.2) 3 (0.5) 2.30 (1.04, 3.91) 0.77 (− 0.27, 2.00)
Suicidal ideation 39 (6.0) 38 (5.8) 21 (3.2) 2.77 (0.51, 5.15) 2.61 (0.37, 4.98)
Renal and urinary
Hypertonic bladder 2 (0.3) 7 (1.1) 1 (0.2) 0.15 0.92 (0.10, 2.06)
Skin and subcutaneous tissue
Alopecia 1 (0.2) 7 (1.1) 0 (0.0) 0.15 1.07 (0.49, 2.20)
Hair color changes 12 (1.8) 16 (2.5) 0 (0.0) 1.84 (1.06, 3.19) 2.45 (1.52, 3.95)
Urticaria 14 (2.1) 12 (1.8) 3 (0.5) 1.69 (0.52, 3.16) 1.38 (0.26, 2.78)
Data shown are for adverse events with incidence of ≥ 1% in one or more verubecestat groups and where the lower bound of the 95% confidence interval for the
difference versus placebo is > 0 in at least one verubecestat group
aConfidence intervals only produced for those comparisons for which at least one of the treatment groups (verubecestat or placebo) had an incidence ≥ 1%
Table 2 Number (%) of participants with composite adverse events and treatment differences
Composite adverse event Number (%) Treatment difference (95% CI)
12 mg (N = 652) 40 mg (N = 652) Placebo (N = 653) 12 mg vs. placebo 40 mg vs. placebo
Delirium-like events 13 (2.0) 31 (4.8) 22 (3.4) − 1.38 (− 3.26, 0.40) 1.39 (− 0.78, 3.63)
Injury or fall 132 (20.2) 151 (23.2) 103 (15.8) 4.47 (0.30, 8.65) 7.39 (3.10, 11.68)
Overactive bladder symptoms 12 (1.8) 27 (4.1) 12 (1.8) 0.00 (− 1.56, 1.57) 2.30 (0.48, 4.31)
Psychotic symptoms 30 (4.6) 36 (5.5) 20 (3.1) 1.54 (− 0.56, 3.73) 2.46 (0.27, 4.77)
Rash, dermatitis, urticaria 79 (12.1) 66 (10.1) 38 (5.8) 6.30 (3.24, 9.47) 4.30 (1.38, 7.32)
Sleep disturbance 67 (10.3) 55 (8.4) 31 (4.7) 5.53 (2.71, 8.48) 3.69 (1.01, 6.47)
Syncopal like events 26 (4.0) 27 (4.1) 17 (2.6) 1.38 (− 0.58, 3.44) 1.54 (− 0.44, 3.62)
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function tests (Additional file 3: Table S2), or other la-
boratory tests (Additional file 4: Table S3). There were
no cases of drug-induced liver injury.
Falls and injuries
Fall and injury adverse event terms were combined into
a composite term because on review of the narratives,
many injury adverse events were noted to be due to a
fall; per data entry conventions, the injury adverse event
caused by the fall, and not necessarily the fall itself, was
entered as the adverse event. Hip and femur fractures
were the most common type of injury. Both verubecestat
12 mg and 40 mg showed an increase versus placebo in
the injury or fall composite term (20.2 and 23.3% vs.
15.8%, Table 2). A Kaplan-Meier plot of the fall/injury
composite term suggested that the treatment difference
Table 3 Linear logistic regression models of time weighted AUC0–24 h by adverse event (N = 1465 participants)
Adverse event Estimate (standard error) Odds ratio (95% CI) P value
Insomnia/sleep disorders − 0.0919 (0.0479) 0.912 (0.830, 1.002) 0.0549
Serious adverse events 0.0470 (0.0285) 1.048 (0.991, 1.108) 0.0989
Psychotic symptoms 0.2671 (0.1959) 1.306 (0.890, 1.917) 0.1728
Muscle spasm 0.1047 (0.0810) 1.110 (0.947, 1.301) 0.1963
Anxiety 0.0611 (0.0475) 1.063 (0.968, 1.167) 0.1987
Rash/dermatitis/urticaria − 0.0363 (0.0466) 0.964 (0.880, 1.057) 0.4356
Diarrhea 0.0267 (0.0441) 1.027 (0.942, 1.120) 0.5444
Falls and injuries − 0.0171 (0.0353) 0.983 (0.917, 1.053) 0.6274
Pain in the extremity 0.0270 (0.0733) 1.027 (0.890, 1.186) 0.7128
Syncope-like (with loss of consciousness) 0.0188 (0.0557) 1.019 (0.914, 1.137) 0.7355
Rash event of clinical interest 0.0176 (0.0585) 1.018 (0.907, 1.141) 0.7639
Weight decreased − 0.0106 (0.0483) 0.989 (0.900, 1.088) 0.8260
Suicidal ideation − 0.0041 (0.0498) 0.996 (0.903, 1.098) 0.9342
AUC0-24 h, area under the concentration time curve within a 24-h dosing interval at steady state
Fig. 1 Kaplan-Meier plot of time to first event of any injury including fall. “Patients at Risk” shows the number of evaluable patients at each time
point by treatment group. “Cases” shows the number of new cases of fall/injury occurring between the corresponding time point and the next
time point (e.g., for 12 mg, there were 43 new cases of fall/injury between week 0 and week 13). A difference in the risk of fall/injury between
verubecestat and placebo became apparent after 13 weeks and then increased over time
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became apparent after 13 weeks and then increased over
time (Fig. 1). No significant exposure-response effect
was seen for the composite term (Table 3). When com-
paring participants with fall/injury versus those without,
there were no marked differences in vital signs (includ-
ing weight change) or related adverse events such as
syncope, dizziness, or cardiac events. Participants with
falls/injuries reported numerically higher rates of pre-
existing medical conditions from a wide range of system
organ class categories, but none appeared higher only in
the verubecestat treated groups. Similarly, participants
with falls/injuries were treated more frequently with
concomitant medications from a wide variety of medica-
tion classes, but none appeared substantially higher only
in the verubecestat groups. Greater age and higher
MMSE scores were associated with increased risk of fall/
injury in all groups including placebo. In the placebo
group, falls/injuries were reported in 18.4% of women
versus 12.7% of men; in the verubecestat groups, the
rates of falls/injuries were similar between men and
women. The percentage of participants with specific ad-
verse events of head injury or skin abrasion adverse
events was increased for the 40mg dose of verubecestat
versus placebo: the overall percentage of participants
reporting these adverse events was < 2% (Table 1). Of
the participants who experienced a fall/injury adverse
event, the numbers (percentages) considered serious
were 17/132 (12.9%), 18/151 (11.9%), and 9/103 (8.7%),
in the 12mg, 40 mg, and placebo groups, respectively.
Syncope-like events were reported for 4.0% and 4.1%
of participants taking verubecestat 12 mg and 40 mg, re-
spectively, versus 2.6% for placebo although the lower
bounds of the 95% CIs for the differences were less than
zero (Table 2). No significant exposure-response effect
was seen (Table 3).
Suicidal ideation
An ECI of suicidal ideation and behavior was defined as
any positive response on the C-SSRS. Therefore, some
events reported may not be new or worsening of a pre-
existing condition. The incidence of ECI of suicidal idea-
tion was higher in the verubecestat 12 mg and 40 mg
groups than the placebo group (6.0% and 5.8% vs. 3.2%;
treatment difference [95% CI] = 2.77 [0.51, 5.15] for 12
mg vs. placebo and 2.61 [0.37, 4.98] for 40 mg vs. pla-
cebo) (Table 1). There did not appear to be an exposure-
response relationship for suicidal ideation (Table 3).
The incidence of treatment-emergent suicidal ideation
or behavior events (i.e., a new or worsening of suicidal
ideation or behavior after the initiation of treatment in
comparison with the period between the screening and
baseline clinic visits) per the C-SSRS was numerically
higher in the verubecestat groups compared with pla-
cebo (Table 4). Treatment-emergent suicidal behavior
was reported by three (0.5%) participants, each in the 12
mg and 40mg groups, and one (0.2%) participant in the
placebo group. Two (0.3%) participants in the 40 mg
group had a suicide attempt and two (0.3%) participants
in the 12 mg group completed suicide. Of the seven par-
ticipants with treatment-emergent suicidal behavior, six
(85.7%) had a history of depression or anxiety and all
were on antidepressants. In addition, six of the seven
participants with suicidal behavior (85.7%) had moderate
dementia at baseline, and six of the seven (85.7%) re-
ported mild-to-moderate psychiatric symptoms (i.e., de-
pression, anxiety, or psychotic symptoms) prior to the
behavior (based on the NPI).
The majority of suicidal ideation events were either
passive or non-specific active thoughts. Regarding more
severe suicidal ideation (active with method or worse),
the majority was reported only at a single clinic visit and
Table 4 Summary of participants with worsening any time postdose on individual domains of the Neuropsychiatric Inventory
Domain 12 mg, n/m (%) 40 mg, n/m (%) Placebo, n/m (%)
Delusions 135/633 (21.3) 124/632 (19.6) 153/639 (23.9)
Hallucinations 84/633 (13.3) 89/632 (14.1) 79/639 (12.4)
Agitation/aggression 245/633 (38.7) 258/632 (40.8) 259/639 (40.5)
Depression/dysphoria 278/633 (43.9) 333/632 (52.7) 256/639 (40.1)
Anxiety 269/633 (42.5) 270/632 (42.7) 250/639 (39.1)
Elation/euphoria 66/633 (10.4) 60/632 (9.5) 62/639 (9.7)
Apathy/indifference 294/633 (46.4) 297/632 (47.0) 306/639 (47.9)
Disinhibition 159/633 (25.1) 155/632 (24.5) 128/639 (20.0)
Irritability/lability 244/633 (38.5) 284/632 (44.9) 244/639 (38.2)
Aberrant motor behavior 177/633 (28.0) 188/632 (29.7) 198/639 (31.0)
Sleep and nighttime behavior disorders 191/633 (30.2) 225/632 (35.6) 182/639 (28.5)
Appetite and eating changes 252/632 (39.9) 255/631 (40.4) 225/639 (35.2)
Worsening was determined by comparing the postdose score to the baseline score
n/m = number of participants with the given item present at that time point/number of participants measured at that time point
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resolved by the next scheduled visit. Two participants in
the 12mg group and one each in the 40mg group and
placebo had more than one occurrence of more severe
suicidal ideation. Four participants discontinued treat-
ment due to suicidal ideation (three on verubecestat,
one on placebo). The majority of participants (67–80%)
who reported any treatment-emergent suicidal ideation
or behavior had a medical history of psychiatric disor-
ders including depression, anxiety, and/or suicidal idea-
tion, which was higher than the overall trial population
(45–48%). Treatment-emergent differences between ver-
ubecestat and placebo occurred within the first 6 months
of treatment but did not progress further through the re-
mainder of the trial (Fig. 2).
Neuropsychiatric symptoms
Verubecestat was associated with increases in the per-
centages of participants with adverse events broadly cat-
egorized as “neuropsychiatric” in nature including
dizziness, anxiety, psychotic-like symptoms (delusions
and hallucinations), and sleep disturbance (Tables 1 and
2). There was no evidence of exposure-response rela-
tionships for these adverse events (Table 3). Regarding
the NPI total scores, in the overall population, there
were no nominally significant differences between the
groups at any time point (Additional file 5: Table S4).
The following individual items showed a numerical in-
crease in the percentages of participants with worsening
any time postdose for both the verubecestat 12 mg and
Table 5 Number (%) of participants with dermatological endpoints and treatment differences
Adverse event category Number (%) Treatment difference (95% CI)
12 mg (N = 652) 40 mg (N = 652) Placebo (N = 653) 12 mg vs. placebo 40 mg vs. placebo
Hypopigmentation composite endpointa 16 (2.5) 16 (2.5) 14 (2.1) 0.31 (− 1.39, 2.04) 0.31 (− 1.39, 2.04)
Hypopigmentation event of clinical interest 10 (1.5) 9 (1.4) 11 (1.7) − 0.15 (− 1.64, 1.32) − 0.3 (− 1.77, 1.12)
Rash event of clinical interest 30 (4.6) 28 (4.3) 8 (1.2) 3.38 (1.63, 5.39) 3.07 (1.36, 5.04)
Severe rashb 0 (0.0) 0 (0.0) 0 (0.0) 0 0
aComprised of the following terms: skin hypopigmentation, skin depigmentation, vitiligo, leukoderma, hypopigmentation of the eyelid, and idiopathic
guttate hypomelanosis
bStevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms
Fig. 2 Kaplan-Meier plot of time to first treatment-emergent suicidal ideation/behavior. This analysis uses the time frame between the screening
and baseline clinic visits as the reference period for determining “treatment-emergent.” “Patients at Risk” shows the number of evaluable patients
at each time point by treatment group. “Cases” shows the number of new cases of suicidal ideation/behavior occurring between the
corresponding time point and the next time point (e.g., for 12 mg, there were 13 new cases of suicidal ideation/behavior between week 0 and
week 13). A difference in the risk of suicidal ideation/behavior between verubecestat and placebo occurred within the first 6 months of treatment
but did not progress further through the remainder of the trial
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40mg dose groups versus placebo (Table 5): hallucina-
tions (13.3 and 14.1% vs. 12.4%), depression/dysphoria
(43.9 and 52.7% vs. 40.1%), anxiety (42.5 and 42.7% vs.
39.1%), disinhibition (25.1 and 24.5% vs. 20.0%), irritabil-
ity/lability (38.5 and 44.9% vs. 38.2%), sleep and night-
time behavior disorder (30.2 and 35.6% vs. 28.5%), and
appetite and eating changes (39.9 and 40.4% vs. 35.2%).
Weight loss
More participants on verubecestat 12 mg and 40 mg had
an adverse event of weight loss versus placebo (6.4 and
6.4% vs. 3.1%, Table 1), and there were more participants
who exceeded the predefined limit of change of a ≥ 7%
decrease versus baseline (23.7 and 29.4% vs. 13.1%, Add-
itional file 2, Table S1). No exposure-response relation-
ship was seen for weight loss adverse events (Table 3).
The verubecestat 40 mg group showed an increase in the
percentage of participants with diarrhea and decreased
appetite adverse events versus placebo (Table 1). The
percentage of participants who showed a worsening on
the “Appetite and eating changes” item of the NPI was
numerically higher for verubecestat 12 mg and 40 mg
versus placebo (39.9% and 40.4% vs. 35.2%, Table 5). Sev-
eral deaths were attributed to metabolism and nutrition
disorders associated with weight loss: failure to thrive
(one participant on 12mg), hypophagia (two participants
on 40mg), and starvation (one participant on placebo).
Dermatological adverse events and hair color change
Dermatological adverse events are summarized in Table 6.
The incidence of rash ECI was higher for participants in
both the verubecestat dose groups versus placebo. There
were no cases of Stevens-Johnson syndrome, toxic epider-
mal necrolysis, or drug-related eosinophilia with systemic
symptoms (DRESS). Most cases of rash were mild to mod-
erate in severity and did not require discontinuation of
study medication. In addition, there was no relationship
between the dose of study medication and the duration of
rash. At the time of the last follow-up, all rashes resolved
or were resolving either with or without concomitant
treatment (e.g., antihistamine or corticosteroids for most
participants) except one participant on 40mg who had
transient mild acantholytic dermatosis that was biopsied
by a dermatologist. The biopsy results were consistent
with Grover’s disease. In addition to rash ECIs, other ad-
verse events similar to rash were also reported, including
dermatitis and urticaria. When these terms were com-
bined together, the incidence was greater for both the ver-
ubecestat groups than for placebo (Table 2).
The incidence of angioedema (standardized MedDRA
query) was 2.3 to 3.2% for verubecestat versus 0.5% for
placebo. In addition, there were six events of swollen face
in five participants taking verubecestat; the participants re-
covered while continuing verubecestat or, in one case, with
a brief interruption of treatment. There was one event of
anaphylaxis (standardized MedDRA query) in a partici-
pant taking verubecestat 40mg. The event was described
as “circulatory collapse” of moderate severity and lasted
for 12 h; verubecestast was interrupted, and the event did
not recur after the treatment initiation.
There were no differences between the groups in the
incidence of skin hypopigmentation events of clinical
Table 6 Most severe treatment-emergent suicidal ideation/behavior event summary
Category 12 mg, n/m (%) 40 mg, n/m (%) Placebo, n/m (%)
With one or more ideation or behavior events 35/651 (5.4) 35/651 (5.4) 21/651 (3.2)
Suicidal ideation 33/651 (5.1) 35/651 (5.4) 21/651 (3.2)
Passive-wish to be dead 18/639 (2.8) 17/642 (2.6) 16/637 (2.5)
Active-non-specific (without regard to method, intent, or plan) 9/645 (1.4) 7/650 (1.1) 1/647 (0.2)
Active-method (without regard to intent or plan) 3/647 (0.5) 5/650 (0.8) 3/649 (0.5)
Active-method and intent (without regard to plan) 2/651 (0.3) 3/651 (0.5) 0/651 (0.0)
Active-method, intent, and plan 1/651 (0.2) 3/651 (0.5) 1/651 (0.2)
Suicidal behavior 3/651 (0.5) 3/651 (0.5) 1/651 (0.2)
Preparatory actions or behaviors 1/651 (0.2) 0/651 (0.0) 0/651 (0.0)
Aborted attempt 0/651 (0.0) 0/651 (0.0) 1/651 (0.2)
Interrupted attempt 0/651 (0.0) 1/651 (0.2) 0/651 (0.0)
Suicide attempt 0/651 (0.0) 2/651 (0.3) 0/651 (0.0)
Completed suicide 2/651 (0.3) 0/651 (0.0) 0/651 (0.0)
Non-suicidal self-injurious behavior 1/651 (0.2) 1/651 (0.2) 0/651 (0.0)
This analysis uses the time frame between the screening and baseline clinic visits as the reference period for determining “treatment-emergent.” For each
category, the population (=m) only includes treated participants for whom worsening from the reference period was possible. For suicidal ideation categories,
worsening is defined as an increasing progression from one category to another along the spectrum (from passive down to active—method, intent, and plan). For
suicidal behavior categories, worsening is defined as an increasing progression from one category to another along the spectrum (from preparatory actions or
behaviors down to completed suicide)
Egan et al. Alzheimer's Research & Therapy           (2019) 11:68 Page 8 of 12
interest or in a prespecified composite endpoint which
included all observed adverse event terms related to re-
duced skin pigment (Table 6).
Hair color change was reported in 1.8% and 2.5% of
participants on verubecestat 12 mg and 40mg, respect-
ively, versus no participants on placebo (Table 1). Most
instances were mild in severity, and none led to treat-
ment discontinuation.
Deaths
As previously reported, there were nine deaths in the 12
mg group, 12 deaths in the 40mg group, and five deaths
in the placebo group [14]. Deaths related to suicides and
weight loss are described in the relevant sections above.
In addition, there were three deaths due to drowning in
the verubecestat groups (one in the 12mg group and
two in the 40mg group) versus none in the placebo
group. The drownings occurred while participants were
bathing unsupervised, and it is uncertain whether they
were associated with syncope or suicidal ideation. How-
ever, none of the participants who drowned had a prior
history of syncope or suicidal ideation. The drownings
all occurred in Japan, where bathtubs are often deeper
than in other countries. Future trials of AD treatments
should consider recommending that participants be su-
pervised while bathing, particularly in Japan.
Discussion
The results from the EPOCH trial indicated that BACE1
inhibition by verubecestat was generally well-tolerated
over 78 weeks in participants with mild-to-moderate
AD. Relatively few participants discontinued verubece-
stat due to adverse events (~ 9% vs. 6% for placebo).
Nevertheless, verubecestat was associated with adverse
events which should be considered in evaluating the
benefit-risk profile of BACE inhibitors.
Falls and injuries are common in the elderly, but
verubecestat was associated with an increase versus
placebo. The reason for the apparent increase is un-
certain but could be multifactorial given that verube-
cestat was also associated with numerically higher
incidences of adverse events that could contribute to
falls such as dizziness, sleep disturbance, and
syncope-like events. There were no marked differ-
ences between verubecestat and placebo in vital signs
(other than weight) or ECG parameters and no obvi-
ous risk factors that contributed to the difference.
There was an increase in syncopal-like adverse events
in the verubecestat groups versus placebo but no
clear relationship to falls/injuries. Falls are a leading
cause of morbidity and mortality in the elderly [21].
While causes appear to be multifactorial, medication
use is thought to play a role [22]. An increased risk
for falls/injuries has been observed for other central
nervous system (CNS) medications in the elderly [23,
24]. Specific interventions that may reduce falls such
as risk management education for the caregiver, and
medication management, should be considered in the
context of future trials of BACE inhibitors [21].
Prior reports have suggested that the incidence of sui-
cidal ideation in AD may be low [25]. Possible increase
in suicidal ideation is a concern for all CNS drugs [26].
Accordingly, in the EPOCH trial suicidal ideation was
assessed at every visit, and treatment-emergent changes
were considered ECI. Three percent of those in the pla-
cebo group reported suicidal ideation compared to 5.4%
in those taking verubecestat. The majority of these
events were passive or non-specific active thoughts.
However, there were two completed suicides and one
attempted suicide, all of which occurred on verubecestat.
There was also an increase in the percentages of partici-
pants who reported neuropsychiatric symptoms such as
sleep disturbance, psychotic-like symptoms (delusions
and hallucinations), and anxiety with verubecestat treat-
ment. Future trials of BACE inhibitors should monitor
participants for the changes in behavior and psychiatric
signs or symptoms.
Verubecestat was associated with weight loss that
amounted to a mean decrease of − 1.4 and − 1.7 kg in
the verubecestat 12 mg and 40 mg groups versus a
mean 0.1 kg increase in the placebo group at week 78
[14]. There was a doubling in the percentage of par-
ticipants with weight loss adverse events and who
exceeded the prespecified ≥ 7% weight decrease limit
for verubecestat versus placebo. In addition, an in-
creased percentage of participants on verubecestat
showed worsening on the appetite item of the NPI
and had an increase in gastrointestinal adverse events
such as diarrhea. There were three deaths in the verubece-
stat groups attributable to disorders associated with
weight loss. It is not known if weight loss is a class effect
of BACE1 inhibitors or specific to verubecestat.
There was an increase in rash-related adverse events
for verubecestat versus placebo. Most of these were
treatable with antihistamines and/or corticosteroids and
generally did not result in study discontinuation. It is
unclear whether this is a mechanism-based effect or spe-
cific to verubecestat. However, development of another
BACE inhibitor, BI 1181181, was reportedly terminated
following the observation of rash in participants in an
early phase dose-ranging trial [27].
Verubecestat also resulted in hair color change in a
small percentage (~ 3%) of participants. Given that hair
color change was not reported in any participants in the
placebo group, BACE2 (and possibly also BACE1) has
been shown to contribute to fur pigmentation in animals
[28, 29], and verubecestat is an inhibitor of BACE2 as
well as BACE1 [13], it is reasonable to assume that this
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is an effect related to BACE2 and/or BACE1 inhibition.
There were no treatment-related differences in the inci-
dence of skin hypopigmentation or related events. From
a participant perspective, hair color change was not
troublesome and no participants discontinued treatment
because of it. In a clinical trial setting, the occurrence of
hair color change raises the possibility of unblinding for
a small number of participants.
Aside from BACE2 inhibition, the only other signifi-
cant off-target (non-BACE1) activity of verubecestat is
the inhibition of the hERG channel which is a common
cause of QTC prolongation and cardiac arrhythmias [13].
However, at therapeutic doses, verubecestat has a rela-
tively little hERG activity [13] and no significant QTC
prolongation was observed in EPOCH. Small increases
in QTC were observed in phase 1 trials at doses of ≥ 300
mg [13], much higher than the maximum dose evaluated
in EPOCH.
The clinical development of several other BACE1 in-
hibitors was discontinued due to liver toxicity/elevated
liver enzymes [30, 31]. There were no clinically signifi-
cant liver enzyme elevations in the EPOCH trial, sug-
gesting that the observation with other BACE inhibitors
is not a class effect. ARIAs have been reported for
monoclonal antibodies [6–9], but there were no differ-
ences in the proportions of patients with ARIAs between
verubecestat and placebo in EPOCH [14]. The clinical
significance of ARIAs is unclear, but in some cases, they
have been associated with clinical manifestations [9, 32].
As noted in the introduction, in an imaging substudy
of EPOCH, verubecestat reduced MRI hippocampal vol-
ume from week 13 to week 78 compared to placebo (re-
duction of ~ 5.7% vs. 5.0%) [14, 33]. Similar reductions
have been reported with other anti-amyloid therapies,
and the clinical significance is unknown [34, 35]. In pre-
vious cases, it has been postulated that the increased re-
duction reflected detrimental (e.g., neurodegeneration)
or beneficial (e.g., reduced inflammation, reduced pla-
ques) effects [34, 35]. Further analyses to understand
this finding are being performed and will be the subject
of a separate paper.
We also noted in the introduction that in EPOCH,
there was a modest initial worsening in mean cogni-
tion scores for verubecestat versus placebo at week
13 that was not maintained at week 78 [14]. For the
40 mg group, this amounted to a 0.8-point difference
from placebo in ADAS-Cog11 score at week 13. Ad-
verse event reports of cognitive impairment were
rare, suggesting that the clinical impact of any treat-
ment-related cognitive worsening was not obvious to
clinicians and patients/caregivers, although this
might have been influenced by the expectation of
cognitive decline in this population. Results from the
APECS trial of verubecestat in prodromal AD also
showed an early-onset worsening in cognition (and
additionally function) associated with verubecestat
treatment [36]. Given that these are post hoc find-
ings of relatively small magnitude, they should be
treated with caution. However, there have been pre-
liminary reports of cognitive worsening for two other
BACE inhibitors [37, 38]. Speculatively, the cognitive
worsening could be due to several different factors
that might, for example, include effects on other
(non-APP) BACE substrates or off-target (e.g.,
BACE2) effects [10, 11]. Regarding the time course
of cognitive worsening in EPOCH, one possible ex-
planation is that the AD pathology-driven cognitive
decline may be larger than the BACE effect and
make it more difficult to detect as the disease pro-
gresses in later stages. Further analyses to under-
stand the effects of verubecestat on cognition are
being performed and will be the subject of a separ-
ate paper.
Conclusions
In conclusion, although verubecestat was generally well
tolerated over 78 weeks of treatment in patients with
mild-to-moderate AD, its safety profile was not as favor-
able as anticipated on the basis of preclinical and phase
1 findings. The increased risk of falls/injuries is notable
as no clear set of risk factors or premonitory signs or
symptoms were found. Increased risk of suicidal ideation
was also observed, particularly within the first 6 months,
and appeared to be predominantly mild and of short
duration. The increased risk was associated with a prior
history of psychiatric disorders. It is not possible to de-
termine which of the increased adverse events are spe-
cific to verubecestat and which represent a class effect.
Future trials of other BACE inhibitors may shed light on
this issue. Differences between selective BACE1 inhibi-
tors and combined BACE1/BACE2 inhibitors such as
verubecestat may emerge. Although there were some
dose-related numerical differences in the incidence rate
of some adverse events, no statistically significant expos-
ure dependencies were observed in the exposure-re-
sponse analysis, suggesting that the adverse event profile
is similar across exposures from 12 to 40mg. Data from
the APECS trial of verubecestat in prodromal AD
showed a broadly similar safety and tolerability profile to
that reported here [36].
Additional files
Additional file 1: Trial protocol. (PDF 10847 kb)
Additional file 2: Table S1. Number (%) of Participants Exceeding the
Predefined Limits of Change in Vital Signs and ECG Measurements.
(DOCX 21 kb)
Egan et al. Alzheimer's Research & Therapy           (2019) 11:68 Page 10 of 12
Additional file 3: Table S2. Number of Participants with Liver Function
Laboratory Findings that Met Predetermined Criteria. (DOCX 21 kb)
Additional file 4: Table S3. Number (%) of Participants Exceeding the
Predefined Limits of Change in Laboratory Parameters. (DOCX 36 kb)
Additional file 5: Table S4. Mixed-Model Analyses for Neuropsychiatric
Inventory Total Score. (DOCX 19 kb)
Abbreviations
AD: Alzheimer’s disease; APP: Amyloid precursor protein; ARIA: Amyloid-
related imaging abnormality; AUC: Area under the curve; Aβ: Amyloid-β;
BACE1: β-Site amyloid precursor protein cleaving enzyme 1; BACE2: β-Site
amyloid precursor protein cleaving enzyme 2; C-SSRS: Columbia Suicide
Severity Rating Scale; ECG: Electrocardiogram; ECI: Event of clinical interest;
MedDRA: Medical Dictionary for Regulatory Activities; MMSE: Mini-Mental
State Exam; NPI: Neuropsychiatric Inventory
Acknowledgements
Julie Passarell from Cognigen conducted the exposure-response analyses.
Sheila Erespe from MSD assisted with the submission of the manuscript. We
thank the patients, caregivers, and families who participated in the trial; the
site investigators and their staff; and the members of the trial committees.
Authors’ contributions
MFE, YM, TV, JK, JLC, PNT, PSA, BV, and DM contributed to the design of the
study. CF, EM, YM, and TV contributed to the study administration. JK and JS
analyzed the data. CL and MFE drafted the manuscript. All authors
contributed to the interpretation of the data, review of the drafts of the
manuscript, and approval of the final version.
Funding
Supported by MSD (Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
Inc., Kenilworth, NJ, USA).
Availability of data and materials
MSD’s data sharing policy, including restrictions, is available at http://
engagezone.msd.com/ds_documentation.php. Requests for access to the
clinical trial data can be submitted through the EngageZone site or via email
to dataaccess@merck.com.
Ethics approval and consent to participate
The trial was a large multicenter study and was approved by the relevant
institutional review board for each site. Written informed consent was




MFE, YM, TV, JK, JS, CF, EM, CL, and DM are current or former employees of,
and own/owned stock in, MSD.
JLC has received in-kind research support from Avid Radiopharmaceuticals
and Teva Pharmaceuticals and has served as a consultant to the following
companies: Acadia, Accera, Actinogen, ADAMAS, Alkahest, Allergan, Alzheon,
Avanir, BiOasis Technologies, Biogen, Boehinger-Ingelheim, Bracket, Casava,
Eisai, GE Healthcare, Genentech, Grifols, Kyowa, Lundbeck, Medavante, MSD,
Nutricia, Orion, Otsuka, Pfizer, QR Pharma, Resverlogix, Roche, Samus,
Samumed, Suven, Takeda, Toyoma, United Neuroscience. He owns stock in
ADAMAS, Prana, Sonexa, MedAvante, Neurotrax, and Neurokos. He is the
copyright holder on the Neuropsychiatric Inventory. He receives support
from Keep Memory Alive and COBRE award P20GM109025.
PNT has received consulting fees from Acadia, Abbott Laboratories, AbbVie,
AC Immune, Auspex, Boehringer-Ingelheim, Chase Pharmaceuticals, Eisai,
GliaCure, Insys Therapeutics, and Pfizer. He has received consulting fees and
research support from AstraZeneca, Avanir, Eli Lilly, Lundbeck, MSD, Roche,
and research support only Amgen, Avid, Biogen, Elan, Functional Neuromo-
dulation (f (nm)), GE Healthcare, Genentech, Novartis, and Targacept. He has
received other research support from the NIA and Arizona Department of
Health Services and holds stock options in ADAMAS.
PSA has served as a consultant to the following companies: NeuroPhage, Eli
Lilly, MSD, Avanir, Roche, Novartis, Pfizer, AstraZeneca, Janssen, Lundbeck,
Biogen, Probiodrug, Anavex, Abbvie, Janssen, Cytox, and aTyr. He receives
research support from Eli Lilly, Janssen, the Alzheimer’s Association, and the
NIH.
BV has served as a consultant to the following companies: Transition
Therapeutics, Takeda, Otsuka, Lilly, Nestlé, MSD, Biogen, and Roche. He
receives research support from Abbvie, Lilly, MSD, Otsuka, Sanofi, Alzheon,
Astra-Zénéca, LPG Systems Nestlé, The Alzheimer’s Association, The Alzhei-
mer Drug Discovery Foundation, The European Commission, and French
Ministry of Health.
Author details
1Merck & Co., Inc., Kenilworth, NJ, USA. 2University of Nevada Las Vegas
Department of Brain Health, Cleveland Clinic Lou Ruvo Center for Brain
Health, Las Vegas, NV, USA. 3Banner Alzheimer’s Institute, Phoenix, AZ, USA.
4University of Southern California, San Diego, CA, USA. 5Gerontopole, INSERM
U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University
Hospital, Toulouse, France. 6Merck & Co., Inc., UG 4C-06, P.O. Box 1000, North
Wales, PA 19454-1099, USA.
Received: 19 March 2019 Accepted: 9 July 2019
References
1. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL.
Alzheimer’s disease. Nat Rev Dis Primers. 2015;1:15056.
2. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S,
Van der Flier WM. Alzheimer’s disease. Lancet. 2016;388(10043):505–17.
3. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25
years. EMBO Mol Med. 2016;8(6):595–608.
4. Yan R, Vassar R. Targeting the beta secretase BACE1 for Alzheimer’s disease
therapy. Lancet Neurol. 2014;13(3):319–29.
5. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, et al.
Safety and tolerability of the gamma-secretase inhibitor avagacestat in a
phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012;
69(11):1430–40.
6. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3
trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med.
2013;369(4):341–50.
7. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3
trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J
Med. 2014;370(4):311–21.
8. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two
phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N
Engl J Med. 2014;370(4):322–33.
9. Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The
antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature.
2016;537(7618):50–6.
10. Vassar R, Kuhn PH, Haass C, Kennedy ME, Rajendran L, Wong PC, et al.
Function, therapeutic potential and cell biology of BACE proteases: current
status and future prospects. J Neurochem. 2014;130(1):4–28.
11. Barao S, Moechars D, Lichtenthaler SF, De Strooper B. BACE1 physiological
functions may limit its use as therapeutic target for Alzheimer’s disease.
Trends Neurosci. 2016;39(3):158–69.
12. Scott JD, Li SW, Brunskill AP, Chen X, Cox K, Cumming JN, et al. Discovery of
the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative verubecestat (MK-
8931)-a beta-site amyloid precursor protein cleaving enzyme 1 inhibitor for
the treatment of Alzheimer’s disease. J Med Chem. 2016;59(23):10435–50.
13. Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF,
et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS beta-
amyloid in animal models and in Alzheimer’s disease patients. Sci Transl
Med. 2016;8(363):363ra150.
14. Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, et al.
Randomized trial of verubecestat for mild-to-moderate Alzheimer’s disease.
N Engl J Med. 2018;378(18):1691–703.
15. Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings J, et al. BACE inhibition by
verubecestat produces a rapid, non-progressive reduction in brain and hippocampal
volume in Alzheimer’s disease. J Prev Alzheimers Disease. 2018;5(4):S18–9.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.
Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work
Group under the auspices of Department of Health and Human Services
Task Force on Alzheimer’s disease. Neurology. 1984;34(7):939–44.
Egan et al. Alzheimer's Research & Therapy           (2019) 11:68 Page 11 of 12
17. American Psychiatric Association. Diagnostic and statistical manual of
mental disorders, 4th edition, text revision (DSM-IV-TR); 2000.
18. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical
method for grading the cognitive state of patients for the clinician. J
Psychiatr Res. 1975;12(3):189–98.
19. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA,
et al. The Columbia-Suicide Severity Rating Scale: initial validity and
internal consistency findings from three multisite studies with
adolescents and adults. Am J Psychiatry. 2011;168(12):1266–77.
20. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA,
Gornbein J. The Neuropsychiatric Inventory: comprehensive
assessment of psychopathology in dementia. Neurology. 1994;44(12):
2308–14.
21. Guirguis-Blake JM, Michael YL, Perdue LA, Coppola EL, Beil TL. Interventions to
prevent falls in older adults: updated evidence report and systematic review
for the US Preventive Services Task Force. JAMA. 2018;319(16):1705–16.
22. Fernando E, Fraser M, Hendriksen J, Kim CH, Muir-Hunter SW. Risk factors
associated with falls in older adults with dementia: a systematic review.
Physiother Can. 2017;69(2):161–70.
23. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA.
Meta-analysis of the impact of 9 medication classes on falls in elderly
persons. Arch Intern Med. 2009;169(21):1952–60.
24. Seppala LJ, Wermelink A, de Vries M, Ploegmakers KJ, van de Glind EMM,
Daams JG, et al. Fall-risk-increasing drugs: a systematic review and meta-
analysis: II. Psychotropics. J Am Med Dir Assoc. 2018;19(4):371.e11–7.
25. Conejero I, Navucet S, Keller J, Olie E, Courtet P, Gabelle A. A complex
relationship between suicide, dementia, and amyloid: a narrative review.
Front Neurosci. 2018;12:371.
26. Guidance for Industry. Suicidal ideation and behavior: prospective
assessment of occurrence in clinical trials. https://www.fda.gov/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm315156.htm.
Accessed 13 Mar 2019.
27. Vitae Pharmaceuticals. BACE inhibitor BI 1181181 voluntarily put on
temporary clinical hold for safety evaluation. Feb 26, 2015. https://www.
globenewswire.com/news-release/2015/02/26/710476/10122212/en/BACE-
Inhibitor-BI-1181181-Voluntarily-Put-on-Temporary-Clinical-Hold-for-Safety-
Evaluation.html. Accessed 4 June 2019.
28. Shimshek DR, Jacobson LH, Kolly C, Zamurovic N, Balavenkatraman KK, Morawiec
L, et al. Pharmacological BACE1 and BACE2inhibition induces hair
depigmentation by inhibiting PMEL17 processing in mice. Sci Rep. 2016;6:21917.
29. Rochin L, Hurbain I, Serneels L, Fort C, Watt B, Leblanc P, et al. BACE2
processes PMEL to form the melanosome amyloid matrix in pigment cells.
Proc Natl Acad Sci U S A. 2013;110(26):10658–63.
30. May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, et al. The potent
BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic
responses in mice, dogs, and humans. J Neurosci. 2015;35(3):1199–210.
31. Janssen Global. Update on Janssen’s BACE Inhibitor Program. https://www.
janssen.com/update-janssens-bace-inhibitor-program. Accessed 4 June 2019.
32. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al.
Amyloid-related imaging abnormalities in patients with Alzheimer’s
disease treated with bapineuzumab: a retrospective analysis. Lancet
Neurol. 2012;11(3):241–9.
33. Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings J, et al. BACE
inhibition by verubecestat produces a rapid non-progressive
reduction in brain and hippocampal volume in Alzheimer’s disease.
JPAD. 2018;5:S19.
34. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of
Aβ immunization (AN1792) on MRI measures of cerebral volume in
Alzheimer disease. Neurology. 2005;64(9):1563–72.
35. Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, et al. Changes in brain
volume with bapineuzumab in mild to moderate Alzheimer’s disease. J
Alzheimers Dis. 2016;49(4):1123–34.
36. Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. Randomized trial of
verubecestat for prodromal Alzheimer’s disease. N Engl J Med. 2019;380(15):1408–20.
37. Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. Preliminary
results of a trial of atabecestat in preclinical Alzheimer’s disease. N Engl J
Med. 2019;380(15):1483–5.
38. Knopman DS. Lowering of amyloid-beta by β-secretase inhibitors – some
informative failures. N Engl J Med. 2019;380(15):1476–8.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Egan et al. Alzheimer's Research & Therapy           (2019) 11:68 Page 12 of 12
